Biolife Solutions INC Form 4 insider transactions

Biolife Solutions Chief Marketing Officer Todd Berard reported a transaction involving the sale of common stock.

Biolife Solutions Chief Financial Officer, Troy Wichterman, reported a transaction involving the sale of company stock.

BioLife Solutions' Chief Quality and Operations, Karen A. Foster, sold 2,577 shares of common stock under a pre-arranged 10b5-1 trading plan.

BioLife Solutions President and CEO Roderick de Greef reported a disposition of 11,101 common shares to cover tax withholding obligations related to restricted stock unit release.

BioLife Solutions' Chief Marketing Officer, Todd Berard, disposed of 1,879 common shares at $19.12 each to cover tax withholding obligations related to restricted stock unit release.

BIOLIFE SOLUTIONS INC's Chief Technology Officer, Sean Werner, disposed of 1,681 shares of common stock to cover tax withholding obligations.

BioLife Solutions' Chief Financial Officer, Troy Wichterman, disposed of 3,749 common shares to cover tax withholding obligations related to restricted stock unit release.

BioLife Solutions' Chief Human Resources Officer, Sarah Aebersold, reported a future disposition of 931 common shares to cover tax withholding obligations related to restricted stock unit vesting on March 19, 2026.

BIOLIFE SOLUTIONS Chief Quality and Operations Officer Karen A. Foster disposed of 1,907 shares of common stock to cover tax obligations related to restricted stock units.

BIOLIFE SOLUTIONS EVP & Chief Scientific Officer Aby J. Mathew disposed of 2,255 common shares to cover tax withholding obligations.

BioLife Solutions' Chief Technology Officer, Sean Werner, sold 111 shares of common stock on March 3, 2026, to cover tax withholding obligations.

BioLife Solutions' Chief Quality and Operations Officer, Karen A. Foster, sold 418 shares of common stock to cover tax withholding obligations.

BioLife Solutions' EVP & Chief Scientific Officer, Aby J. Mathew, sold 529 shares of common stock to cover tax withholding obligations.

BioLife Solutions' CFO, Troy Wichterman, sold 588 shares of common stock at $20.74 per share to cover tax withholding obligations.

BIOLIFE SOLUTIONS' Chief Human Resources Officer, Sarah Aebersold, sold 219 shares of common stock at $20.74 per share to cover tax withholding obligations.

BioLife Solutions' Chief Marketing Officer, Todd Berard, sold 353 shares of common stock to cover tax withholding obligations.

BioLife Solutions Chief Marketing Officer Todd Berard increased his direct beneficial ownership of common stock through restricted stock grants, partially offset by shares withheld for taxes.

Amy DuRoss, a Director at BioLife Solutions Inc., acquired 8,170 shares of common stock through a restricted stock grant.

BioLife Solutions' Chief Financial Officer, Troy Wichterman, received substantial restricted stock awards, reflecting performance and future compensation.

BioLife Solutions Director Anthony Hunt acquired 8,170 shares of common stock, increasing his direct beneficial ownership to 15,046 shares.

Catherine Coste, a Director at BioLife Solutions Inc., was granted 8,170 shares of common stock as part of the company's 2023 Performance Incentive Plan.

BioLife Solutions Director Rachel Ellingson acquired 8,170 shares of common stock as part of the company's 2023 Performance Incentive Plan.

BioLife Solutions Inc. CEO Roderick de Greef acquired over 500,000 shares through restricted stock awards, demonstrating strong performance-based vesting.

BioLife Solutions' EVP & Chief Scientific Officer, Aby J. Mathew, reported the acquisition of restricted stock awards and a related tax withholding transaction.

BioLife Solutions' Chief Human Resources Officer, Sarah Aebersold, vested 23,548 performance-based restricted stock units and subsequently sold 5,734 shares to cover tax obligations.

BioLife Solutions' Chief Technology Officer, Sean Werner, was granted 24,116 shares of common stock as part of his 2026 compensation, vesting over four years.

BioLife Solutions director Timothy L. Moore acquired 8,170 shares of common stock as restricted stock under the company's 2023 Performance Incentive Plan.

BioLife Solutions' Chief Quality and Operations, Karen A. Foster, reported the vesting of restricted stock and subsequent tax-related share withholding.

Joydeep Goswami, a Director at BioLife Solutions Inc., acquired 8,170 shares of common stock through a restricted stock grant.

BioLife Solutions' Chief Financial Officer, Troy Wichterman, sold 990 shares of common stock at $25.59 per share to cover tax withholding obligations.